東山精密(002384.SZ)跌幅收窄至4.62%:“丟單”系舊聞,問題早已解決並量產
格隆匯11月11日丨因“丟單”傳聞盤中一度大跌8.85%的東山精密(002384.SZ)最終收跌4.62%,收報19.84元,成交12.12億元,最新總市值319億元。此前網傳東山精密PCB子公司部分產品破孔無法出貨,良品率偏低,蘋果將訂單轉交臻鼎-KY、台郡。對於PCB業務收入佔比高達55.12%,淨利佔比高達50.58%的東山精密來説這一傳聞無疑是重大利空。今日午間,東山精密相關負責人緊急參與了電話澄清會議。有參會人士表示,所謂“丟單”傳言其實是6月份就出現了。事實是:東山精密子公司mflex在6月份研發、試生產時出現小問題,後來也都已經解決並順利量產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.